ArticleBMC cancer2025
PLCD1 expression for early detection and prognosis in High-Grade serous ovarian cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHigh-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of epithelial ovarian cancer, characterized by rapid progression and poor prognosis. Despite advances in treatment, most cases are diagnosed at an advanced stage, and current diagnostic markers such as CA-125 have limited utility for early detection or treatment stratification. This study aimed to investigate the clinical significance and biological Function of phospholipase C delta 1 (PLCD1) in HGSOC.
methodsPLCD1 expression was assessed by immunohistochemistry (IHC) using tissue microarrays (TMA) comprising normal, borderline, and HGSOC tissues. Survival analyses were performed using Kaplan-Meier methods. PLCD1 expression in HGSOC cell lines was evaluated by Western blotting. Functional studies were conducted using PLCD1 knockdown and overexpression cell lines. Cell proliferation, invasion, and 3D spheroid assays were used to assess tumor cell behavior. A xenograft mouse model was used to evaluate the effect of PLCD1 overexpression on tumor growth in vivo.
resultsPLCD1 expression was significantly elevated in HGSOC tissues compared to normal and borderline tissues. Low PLCD1 expression was associated with significantly worse overall and disease-free survival in patients with HGSOC (n = 101). In vitro, PLCD1 knockdown increased proliferation in OVCA429 cells, while overexpression in OVCAR3 cells suppressed colony formation. In vivo, PLCD1 overexpression significantly reduced tumor growth in a xenograft model.
conclusionPLCD1 functions as a tumor suppressor in HGSOC and is associated with improved clinical outcomes. These findings suggest that PLCD1 may serve as a prognostic biomarker and potential therapeutic target in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.